Jasper Therapeutics adds CEO vesting acceleration, extends chairperson term

Jasper Therapeutics, Inc.

Chairperson William Lis term extended to Mar 15, 2024; annual cash comp reduced to $125K from $250K effective Apr 1, 2023.
CEO Ronald Martell: if terminated without cause/good reason within 24 months post-Change in Control, receives 18 months base salary plus full equity vesting.
Change in Control defined by reference to Jasper's Severance Plan; amendments effective April 13, 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.